がん生検市場：製品タイプ別、適応症別-2025-2030年の世界予測

がん生検市場は、2023年に298億4,000万米ドルと評価され、2024年には334億8,000万米ドルに達すると予測され、CAGR 12.28％で成長し、2030年には671億4,000万米ドルに達すると予測されています。

がん生検市場には、がんの診断とモニタリングのために組織サンプルを採取する一連の手順が含まれます。生検は、がんの確定診断を提供し、医師が効果的な治療戦略を立案できるようにするために極めて重要です。この市場には、針生検や外科的生検のような伝統的な手法のほか、体液中のバイオマーカーを分析するリキッドバイオプシーのような新しい手法も含まれます。生検の必要性は、世界のがん罹患率の増加と侵襲性の低い診断ツールに対する需要の高まりによって強調されています。生検は、病院、診断センター、研究機関など、複数の最終用途分野で利用されています。この市場の主な成長促進要因には、生検技術の進歩、個別化医療の導入の高まり、ヘルスケア支出の増加などがあります。AIを活用した画像診断・分析ツールの開発は、診断の合理化と精度の向上という大きな機会をもたらします。しかし、先進的な生検方法は比較的高価であること、規制上のハードル、侵襲的な処置に対する患者の消極性などの限界に市場は直面しています。課題としては、熟練した専門家の不足、低リソース環境における技術格差なども挙げられます。企業にとって、リキッドバイオプシーのような非侵襲的生検技術の革新は、がんを早期発見できる可能性があることから、極めて重要です。さらに、自動生検技術やリアルタイムのデータ分析システムに投資することで、市場での地位を高め、個別化された治療計画に貢献することができます。市場は急速な技術進化に牽引される競争市場であるため、企業は継続的な研究開発努力で常に先を行く必要があります。イノベーションを促進し、応用可能性を拡大するために、企業は研究機関とのコラボレーションに注力することが極めて重要です。全体として、アクセシビリティ、費用対効果、技術統合を優先することで、企業はこの進化する市場環境を効果的にナビゲートし、新たな機会を活用することができます。

市場力学：急速に進化するがん生検市場の主要市場インサイトを公開

がん生検市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 非侵襲的手技への嗜好の高まり
  • がん生検と組織切片の重要性の高まり
  • リキッドがん生検の採用拡大
• 市場抑制要因
  • がん生検の感度と特異度の低さ
• 市場機会
  • がん生検デバイスの技術的進歩
  • 新規がん治療のための研究開発活動の活発化
• 市場の課題
  • 厳しい規制要件と不透明な償還シナリオ

ポーターの5つの力：がん生検市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：がん生検市場における外部からの影響の把握

外部マクロ環境要因は、がん生検市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がん生検市場における競合情勢の把握

がん生検市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがん生検市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がん生検市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がん生検市場における成功への道筋を描く

がん生検市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 非侵襲的処置への好みが高まっている
    • がんの生検と組織切片の新たな重要性
    • 液体がん生検の採用増加
  • 抑制要因
    • がん生検の感度と特異度が低い
  • 機会
    • がん生検デバイスの技術的進歩
    • 新たながん治療法の研究開発活動の強化
  • 課題
    • 厳しい規制要件と不明確な償還シナリオ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 がん生検市場：製品別

• 機器
• キットと消耗品
• サービス

第7章 がん生検市場：タイプ別

• 液体生検
• 組織生検
  • 針生検
    • コア針生検
    • 穿刺吸引法
  • 外科的生検

第8章 がん生検市場適応症別

• 血液がん
• 乳がん
• 子宮頸がん
• 大腸がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 卵巣がん
• 膵臓がん
• 前立腺がん
• 皮膚がん

第9章 南北アメリカのがん生検市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のがん生検市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのがん生検市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agena Bioscience, Inc.
• Agilent Technologies Inc.
• ANGLE PLC
• Becton, Dickinson and Company
• BIOCEPT, Inc.
• Danaher Corporation
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Freenome Holdings, Inc.
• GRAIL, Inc.
• Guardant Health
• HelioHealth
• Hologic, Inc.
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Lucence Health Inc.
• MDx Health
• Myriad Genetics, Inc.
• Natera, Inc.
• OncoCyte Corp
• Personalis Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific, Inc.
• Trovagene, Inc

LIST OF FIGURES

• FIGURE 1. CANCER BIOPSY MARKET RESEARCH PROCESS
• FIGURE 2. CANCER BIOPSY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANCER BIOPSY MARKET DYNAMICS
• TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY BLOOD CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY CERVICAL CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY KIDNEY CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY OVARIAN CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY PANCREATIC CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY SKIN CANCERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 49. CANADA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 51. CANADA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 52. CANADA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. CHINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CHINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 78. CHINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 79. CHINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 81. INDIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 83. INDIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 84. INDIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. ITALY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. ITALY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 169. ITALY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 170. ITALY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. POLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. POLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. POLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 189. POLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 190. POLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. QATAR CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 192. QATAR CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. QATAR CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 194. QATAR CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 195. QATAR CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 241. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 242. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

The Cancer Biopsy Market was valued at USD 29.84 billion in 2023, expected to reach USD 33.48 billion in 2024, and is projected to grow at a CAGR of 12.28%, to USD 67.14 billion by 2030.

The cancer biopsy market encompasses the array of procedures used to extract tissue samples for the diagnosis and monitoring of cancerous growths. Biopsies are crucial as they provide definitive cancer diagnoses, enabling physicians to devise effective treatment strategies. This market includes traditional techniques like needle and surgical biopsies, as well as emerging methods such as liquid biopsies, which analyze biomarkers in bodily fluids. The necessity of biopsies is underscored by the increasing global incidence of cancer and the growing demand for less invasive diagnostic tools. Biopsies find application across multiple end-use segments, including hospitals, diagnostic centers, and research institutes. Key growth drivers for this market include advancements in biopsy technologies, the rising adoption of personalized medicine, and increased healthcare spending. The development of AI-driven imaging and analysis tools presents significant opportunities, streamlining diagnosis and improving accuracy. However, the market faces limitations such as the relatively high cost of advanced biopsy methods, regulatory hurdles, and patient reluctance towards invasive procedures. Challenges also include the scarcity of skilled professionals and technological gaps in low-resource settings. For businesses, innovation in non-invasive biopsy techniques like liquid biopsy can be pivotal, given its potential to detect cancers at an earlier stage. Furthermore, investing in automated biopsy technologies and real-time data analysis systems can enhance market position and contribute to personalized treatment plans. The market is competitive, driven by rapid technological evolution, thus requiring companies to stay ahead with ongoing R&D efforts. It's crucial for businesses to focus on collaborations with research institutes to foster innovation and expand applicability. Overall, by prioritizing accessibility, cost-effectiveness, and technological integration, companies can effectively navigate this evolving market landscape and capitalize on emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biopsy Market

The Cancer Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing preference for non-invasive procedures
  • Emerging significance of cancer biopsies and tissue sectioning
  • Growing adoption of liquid cancer biopsies
• Market Restraints
  • Low sensitivity and specificity of cancer biopsies
• Market Opportunities
  • Technological advancements in cancer biopsy devices
  • Increasing R&D activities for novel cancer treatments
• Market Challenges
  • Stringent regulatory requirements and unclear reimbursement scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biopsy Market

A detailed market share analysis in the Cancer Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biopsy Market

A strategic analysis of the Cancer Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments, Kits & Consumables, and Services.
• Based on Type, market is studied across Liquid Biopsies and Tissue Biopsies. The Tissue Biopsies is further studied across Needle Biopsies and Surgical Biopsies. The Needle Biopsies is further studied across Core Needle Biopsy and Fine Needle Aspiration.
• Based on Indication, market is studied across Blood Cancers, Breast Cancer, Cervical Cancers, Colorectal Cancer, Kidney Cancers, Liver Cancers, Lung Cancers, Ovarian Cancers, Pancreatic Cancers, Prostate Cancers, and Skin Cancers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing preference for non-invasive procedures
    • 5.1.1.2. Emerging significance of cancer biopsies and tissue sectioning
    • 5.1.1.3. Growing adoption of liquid cancer biopsies
  • 5.1.2. Restraints
    • 5.1.2.1. Low sensitivity and specificity of cancer biopsies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in cancer biopsy devices
    • 5.1.3.2. Increasing R&D activities for novel cancer treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements and unclear reimbursement scenarios
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Biopsy Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Kits & Consumables
• 6.4. Services

7. Cancer Biopsy Market, by Type

• 7.1. Introduction
• 7.2. Liquid Biopsies
• 7.3. Tissue Biopsies
  • 7.3.1. Needle Biopsies
    • 7.3.1.1. Core Needle Biopsy
    • 7.3.1.2. Fine Needle Aspiration
  • 7.3.2. Surgical Biopsies

8. Cancer Biopsy Market, by Indication

• 8.1. Introduction
• 8.2. Blood Cancers
• 8.3. Breast Cancer
• 8.4. Cervical Cancers
• 8.5. Colorectal Cancer
• 8.6. Kidney Cancers
• 8.7. Liver Cancers
• 8.8. Lung Cancers
• 8.9. Ovarian Cancers
• 8.10. Pancreatic Cancers
• 8.11. Prostate Cancers
• 8.12. Skin Cancers

9. Americas Cancer Biopsy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Biopsy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biopsy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agena Bioscience, Inc.
• 2. Agilent Technologies Inc.
• 3. ANGLE PLC
• 4. Becton, Dickinson and Company
• 5. BIOCEPT, Inc.
• 6. Danaher Corporation
• 7. Epigenomics AG
• 8. Exact Sciences Corporation
• 9. F. Hoffmann-La Roche Ltd.
• 10. Freenome Holdings, Inc.
• 11. GRAIL, Inc.
• 12. Guardant Health
• 13. HelioHealth
• 14. Hologic, Inc.
• 15. Illumina, Inc.
• 16. Laboratory Corporation of America Holdings
• 17. Lucence Health Inc.
• 18. MDx Health
• 19. Myriad Genetics, Inc.
• 20. Natera, Inc.
• 21. OncoCyte Corp
• 22. Personalis Inc.
• 23. QIAGEN N.V.
• 24. Thermo Fisher Scientific, Inc.
• 25. Trovagene, Inc